Solexa
Hayward
About Solexa
Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Total funding: $222.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2006)
- Ticker: nasdaq:SLXA
Industries & Categories
Biotechnology, Genetics, Medical, Medical Device
Canonical: https://fsome.com/organization/solexa-2095719 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.